Key result
Review highlights emerging biomarkers and targeted therapies addressing vitiligo pathogenesis.
Answers are grounded in this paper and cite their sources.
Vitiligo is the most common acquired pigmentary disorder and can have profound negative psychosocial impacts on patients. The disease course of vitiligo is often unpredictable, and diagnosis and treatment of vitiligo remain a challenging dermatological task. In this review, we touch on new advances in understanding vitiligo pathogenesis; discuss emerging biomarkers that may aid physicians in assessing vitiligo disease activity and severity, and summarize prospective targeted therapies in treating vitiligo. A brief outline dedicated to the impact of the coronavirus disease 2019 pandemic on vitiligo patients is also provided. We hope that readers may acquire a more comprehensive understanding of vitiligo and gain insights into new diagnostic tools and therapeutic options for vitiligo.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2023) conducted a review in Vitiligo. This review summarizes recent advances in understanding vitiligo pathogenesis, emerging biomarkers for disease assessment, and prospective targeted therapies for its treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: